drugset / Trial / NCT06001788
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.
Timeline
- Start
- 2024-02-22
- Primary completion
- 2026-08
- Completion
- 2027-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ziftomenib | Small molecule | — | Oral |
| Background | Cytarabine | Small molecule | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |
| Background | Gilteritinib | Small molecule | — | Oral |
| Background | Granulocyte colony-stimulating factor | Protein / enzyme biologic | — | Subcutaneous |
| Background | Idarubicin | Small molecule | — | Intravenous |